Eosinophil and Anticoagulation in COVID-19 Patients

Bursa Postgraduate Hospital

Status: Completed

Conditions: COVID-19

Treatments: Drug: LMWH

Study type: Observational

Funder types: Other

Identifiers

NCT04507282

Bursa Postgraduate Hospital

Details and patient eligibility

About

Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determine the anticoagulant activity of low molecular weight heparin (LMWH) in COVID-19 patients.

Enrollment: 80 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients older than 18 years, who were diagnosed with COVID-19 and were administered LMWH,
• agreed to participate in the study were included

Exclusion criteria

• Patients with previous coagulopathy,
• continuous indication of anticoagulant therapy (atrial fibrillation (AF), valve disease),
• glomerular filtration rate (GFR) <30 mL/min or undergoing dialysis, or with known liver dysfunction were excluded from the study.

Trial design

80 participants in 1 patient group

COVID 19 positive patients

Treatment:

Drug: LMWH